A pan-tissue DNA-methylation epigenetic clock based on deep learning

• Published in: npj aging Vol. 8; no. 1
• Main Authors: de Lima Camillo, Lucas Paulo, Lapierre, Louis R., Singh, Ritambhara
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 19-04-2022; Nature Publishing Group
• Subjects: 631/337; 631/337/176; 631/45; Age; Aging; Binding sites; Biomedical and Life Sciences; Biomedicine; Cell Physiology; Chromatin; CpG islands; Deep learning; Diabetes mellitus (non-insulin dependent); DNA methylation; Epigenetics; Genomes; Geriatrics/Gerontology; HIV; Human immunodeficiency virus; Human Physiology; Mitochondria; Multiple sclerosis; Neural networks; Neurosciences; Predictions; Regulatory sequences
• ISSN: 2731-6068; 2731-6068; 2056-3973
• DOI: 10.1038/s41514-022-00085-y

Several age predictors based on DNA methylation, dubbed epigenetic clocks, have been created in recent years, with the vast majority based on regularized linear regression. This study explores the improvement in the performance and interpretation of epigenetic clocks using deep learning. First, we gathered 142 publicly available data sets from several human tissues to develop AltumAge, a neural network framework that is a highly accurate and precise age predictor. Compared to ElasticNet, AltumAge performs better for within-data set and cross-data set age prediction, being particularly more generalizable in older ages and new tissue types. We then used deep learning interpretation methods to learn which methylation sites contributed to the final model predictions. We observe that while most important CpG sites are linearly related to age, some highly-interacting CpG sites can influence the relevance of such relationships. Using chromatin annotations, we show that the CpG sites with the highest contribution to the model predictions were related to gene regulatory regions in the genome, including proximity to CTCF binding sites. We also found age-related KEGG pathways for genes containing these CpG sites. Lastly, we performed downstream analyses of AltumAge to explore its applicability and compare its age acceleration with Horvath’s 2013 model. We show that our neural network approach predicts higher age acceleration for tumors, for cells that exhibit age-related changes in vitro, such as immune and mitochondrial dysfunction, and for samples from patients with multiple sclerosis, type 2 diabetes, and HIV, among other conditions. Altogether, our neural network approach provides significant improvement and flexibility compared to current epigenetic clocks for both performance and model interpretability.